Bryan Burt, MD
Dr. Bryan Burt is the Chief of Thoracic Surgery and Professor of Surgery at UCLA Health and the David Geffen School of Medicine at UCLA in Los Angeles, California. He is an internationally recognized surgeon-scientist and surgical oncologist who specializes in minimally invasive robotic thoracic surgery for the treatment of lung cancer, esophageal cancer, thymic tumors, and thoracic malignancies. He has a special interest in the treatment of patients with malignant pleural mesothelioma.[1]
Education and Career
Dr. Burt attended New York University as an undergraduate, and then earned his medical degree at Weill Medical College of Cornell University. He completed residencies in General Surgery and Thoracic Surgery at the Brigham and Women’s Hospital and a post-doctoral research fellowship in Cellular Immunology at Memorial Sloan-Kettering Cancer Center.[1]
Dr. Burt spent several years at Baylor College of Medicine in Houston, Texas, where he was a member of the graduate faculty in the Department of Immunology and Microbiology and the Graduate School of Biomedical Sciences, as well as chief of thoracic surgery.
Professional Memberships
Fellow of the American College of Surgeons
Society of Thoracic Surgeons
American Association for Thoracic Surgery
Research
Dr. Burt is a renowned researcher. In addition to his clinical role, he runs a research laboratory in the JCLA Health Jonsson Comprehensive Cancer Center that studies response and resistance mechanisms to immunotherapy in thoracic malignancies, including lung cancer and mesothelioma. He is also investigating a novel proteomics platform for improving intraoperative diagnosis and margin assessment in lung cancer.
His laboratory is NIH-funded and has completed several investigator-initiated clinical trials of novel immunotherapeutic strategies for patients with thoracic malignancies. He has also published extensively and is a Feature Editor at the Journal of Thoracic and Cardiovascular Surgery.[1]
His recent publications include:[2]
- Burt BM, Lee HS, Raghuram AC, Strange C, Mason J, Strange T, Delgado J, Sugarbaker DJ “Preoperative prediction of unresectability in malignant pleural mesothelioma.” J Thorac Cardiovasc Surg.; Pubmed PMID: 32087959
- Lee HS, Jang, HJ, Choi JM, Zhang J, Lenge De Rosen V, Wheeler T, Lee JS, Tu T, Jindra P, Kerman R, Jung SY, Kheradmand F, Sugarbaker DJ, Burt BM “Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.” JCI Insight.; Pubmed PMID: 29618661
- Lee HS, Jang HJ, Shah R, Yoon D, Hamaji M, Wald O, Lee JS, Sugarbaker DJ, Burt BM “Genomic analysis of thymic epithelial tumors identifies novel subtypes associated with distinct clinical features.” Clinical Cancer Research.; Pubmed PMID: 28400429
- Burt BM, Richards WG, Lee HS, Bartel S, Dasilva MC, Gill RR, Jaklitsch MT, Johnson BE, Swanson SJ, Bueno R, Sugarbaker DJ “A phase I trial of surgical resection and intraoperative hyperthermic cisplatin and gemcitabine for pleural mesothelioma.” J Thorac Oncol.; Pubmed PMID: 29753120
